| Active substance | tremelimumab |
| Holder | AstraZeneca AB |
| Status |
closed |
| Indication | as first-line treatment in patients with unresectable hepatocellular carcinoma in combination with Durvalumab (Imfinzi) |
| Public documents | Approbation |
| Approbation amendment | |
| Information for the patient | |
| Informed consent | |
| Last update | 01/02/2024 |